ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025
Intraglandular botulinum toxin in postoperative head and neck fistula: a retrospective analysis.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOrocervical (OCF) or pharyngocutaneous fistula (PCF) are one of the disastrous complications of head and neck cancer surgery. Conventional standards of management are predominantly conservative. Though a majority of such patients respond to conservative management, it nevertheless causes significant delay in wound healing. This study explores the role of intraglandular Botulinum toxin injection in shortening the time to fistula healing.
methodsRetrospective case-control study at a tertiary care oncology center in South Asia from January 2021 to December 2023 on all consecutive patients of OCF/PCF. Patients with any history of head and neck radiation were excluded. The case group received intraglandular (parotid+/-submandibular gland) botulinum toxin injection and conservative management and the control group received only conservative management. The time taken for the fistula to heal was the primary outcome.
results31 patients in case and 104 patients were in control group. The mean time from fistula diagnosis till injection was 5.8 ± 3.1 days and the mean fistula healing time in case group was 18.5 ± 7.15 days (Range:10-34 days). The mean total dose of botulinum toxin was 59.2 ± 22.4 MU (Range: 40 to 100 MU). For control group, the mean time taken for the fistula to heal was 26 ± 15 days (Range:15 to 75 days). The difference was statistically significant (p-0.008, 95% CI: -9.0 to -2.0). Adverse effects attributable to botulinum toxin injection were: pain at the injection site (n = 3) and xerostomia (n = 1). On multivariate analysis, intervention with intraglandular botulinum toxin emerged as an independent variable impacting the time taken for fistula closure.
conclusionThis is the largest study to show the efficacy of intraglandular botulinum toxin injection in reducing the time taken for healing of postoperative salivary fistula with a tolerable adverse effect profile.
Indexed as
Identifiers
39739021What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.